#ASH17: Sy­ros evis­cer­at­ed by in­vestor back­lash as lead drug flails bad­ly in PhII

It didn’t take long Mon­day morn­ing to see who the worst per­former for the ASH week­end would be. Sy­ros $SYRS cratered quick­ly once in­vestors got …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.